Validação e propriedades psicométricas do Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) para a língua portuguesa

Paganotti, Maurício Aquino; Valim, Valéria; Serrano, Érica Vieira; Miyamoto, Samira Tatiyama; Giovelli, Raquel Altoé; Santos, Maria Carmen Lopes Ferreira Silva

doi:10.1016/j.rbr.2015.06.004

Cited by 15 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, ESSPRI total score correlated with both β2 microglobulin and erythrocyte sedimentation rate 28. ESSPRI was recently validated in Portuguese population 29…”

Section: Discussionmentioning

confidence: 99%

Correlation between Xerostomia index, Clinical Oral Dryness Scale, and ESSPRI with different hyposalivation tests

Hijjaw

Alawneh

Ojjoh

et al. 2019

OARRR

View full text Add to dashboard Cite

Background and objectiveXerostomia is a subjective measure of dry mouth, while hyposalivation is an objective measure of reduced saliva flow rate. In this study, we aim to assess the association between commonly used xerostomia scoring systems, with different hyposalivation measures among Sjogren Syndrome (SS) patients.MethodsIn a cohort of SS patients, we assessed xerostomia using Xerostomia index, clinical oral dryness scale (CODS), and the European League Against Rheumatism SS Patient-Reported Index (ESSPRI), and we assessed hyposalivation using unstimulated whole saliva flow (UWS), stimulated whole saliva flow (SWS), and stimulated parotid flow (SPF). We analyzed the association between xerostomia and hyposalivation using association tests in SPSS.ResultsWe included a total of 49 patients in this study, of which 34 (68%) had primary SS, and 15 (32%) had secondary. CODS was significantly correlated with SWS (P=0.048), with a negative correlation coefficient of 0.216, and with SPF (P=0.009), with a negative correlation coefficient of 0.291. The dryness domain of ESSPRI was significantly correlated with UWS (P=0.031) with a negative correlation coefficient of 0.233.ConclusionCODS is the scoring system with the highest correlation with hyposalivation, particularly SWS and SPF, followed by ESSPRI dry domain, which is correlated with UWS. Xerostomia index is not correlated with hyposalivation.

show abstract

“…Interestingly, ESSPRI total score correlated with both β2 microglobulin and erythrocyte sedimentation rate 28. ESSPRI was recently validated in Portuguese population 29…”

Section: Discussionmentioning

confidence: 99%

Correlation between Xerostomia index, Clinical Oral Dryness Scale, and ESSPRI with different hyposalivation tests

Hijjaw

Alawneh

Ojjoh

et al. 2019

OARRR

View full text Add to dashboard Cite

show abstract

“…Currently, the ESSDAI and ESSPRI are the only disease-specific validated clinical scores available for pSS [ 22 , 24 ]. Although the ESSPRI has an acceptable reproducibility, the scores do not necessarily correlate with systemic disease activity [ 31 ]. pSS is characterized by considerable heterogeneity and its spectrum extends from secretory gland dysfunction to systemic involvement with extra-glandular manifestations.…”

Section: Discussionmentioning

confidence: 99%

A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren’s syndrome

Bentley¹,

Fisher

Barone

et al. 2023

Rheumatology

View full text Add to dashboard Cite

Objectives Primary Sjögren syndrome (pSjS) is a chronic autoimmune disorder characterized by mucosal dryness and systemic symptoms. We tested the effects of inhibition of cathepsin S using the potent and selective inhibitor RO5459072 on disease activity and symptoms of pSjS. Methods This was a randomized, double-blind, placebo-controlled, parallel-group, Phase IIA study to investigate the effects of RO5459072 (100 mg twice daily [BID]; 200 mg per day). Seventy-five patients with pSjS were randomized 1:1 to receive either RO5459072 or placebo for 12 weeks. The primary outcome was the proportion of patients with a ≥ 3 point reduction from baseline in European League against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) score. We also investigated the effects of RO5459072 on quality of life, exocrine gland function, biomarkers related to Sjögren’s syndrome, and safety and tolerability. Results The proportion of patients showing an improvement in ESSDAI score was not significantly different between the RO5459072 and placebo arms. No clinically meaningful treatment effects were observed in favor of RO5459072 for all secondary outcomes. Analysis of soluble biomarkers indicated target engagement between RO5459072 and cathepsin S. There were modest decreases in the number of circulating B-cells and T cells in the RO5459072 group, although these did not reach significance. RO5459072 was safe and well-tolerated. Conclusions There was no clinically relevant improvement in ESSDAI score (primary end point), and no apparent benefit in favor of RO5459072 in any of the secondary endpoints. Further work is needed in order to understand the mechanisms of MHC-II-mediated immune stimulation in pSjS. Trial registration ClinicalTrials.gov; NCT02701985

show abstract

“…Clinical items in the analysis were age, gender, smoking, and clinical features, including the presence/absence of respiratory symptoms (cough, dyspnea, phlegm, hemoptysis, and chest pain). At the time of evaluation, the EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and the EULAR Sjögren’s syndrome disease activity index (ESSDAI) were administered to all patients ( 20 – 22 ).…”

Section: Methodsmentioning

confidence: 99%

Radiological patterns and pulmonary function values of lung involvement in primary Sjögren’s syndrome: A pilot analysis

Mormile

Mormile²,

Rossi³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundLung involvement in primary Sjögren’s syndrome (pSS) may vary from 9 to 90%. Interstitial lung disease and tracheobronchial alterations are the most typical findings. The evidence of primarily emphysematous changes at computed tomography of the chest of pSS patients has occasionally been described but poorly characterized. This study aims to assess pulmonary involvement and the impact on respiratory function in a cohort of pSS patients.Materials and methodsA total of 22 consecutive patients diagnosed with pSS underwent pulmonary function tests to investigate the presence of ventilatory impairment and evaluate the exchanges of alveolar gases. All patients underwent a chest high-resolution computed tomography (HRTC).ResultsDynamic volumes were within the normal range in 21 patients (95.4%). A reduction in the diffusing capacity of the lung for carbon monoxide (DLCO) was observed in 18 patients (81.8%). Ten (45.5%) patients showed a mild degree deficit, while 8 patients (36%) showed a moderate degree deficit. Analysis of DLCO revealed a significant difference between pSS patients and controls [t(30.98) = −10.77; p < 0.001], showing a higher DLCO value for the healthy controls (mean ± SE; 101.27 ± 6.08) compared to pSS patients (mean ± SE; 65.95 ± 12.78). Emphysema was found in 21 (94.5%) patients and was the most widespread pulmonary injury. Tracheal thickness was reduced in 15 (67%) patients. Micronodules were observed in 10 (45%) patients in all the pulmonary fields. Bronchial wall thickening and bronchiectasis were observed in 8 (36%) patients, mainly in the lower lobes. Ground glass was found in 5 (22.5%) patients in lower and higher lobes. Cysts were observed in two patients (9%).ConclusionThe reduction of the DLCO could be related to early emphysematous alterations in the absence of spirometric alterations and relevant respiratory symptoms. In conclusion, emphysema might be seen as an early pulmonary involvement mark in patients suffering from pSS.

show abstract

Validação e propriedades psicométricas do Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) para a língua portuguesa

Abstract: The Brazilian Portuguese version of ESSPRI is a valid and reproducible version.

Cited by 15 publications

References 34 publications

Correlation between Xerostomia index, Clinical Oral Dryness Scale, and ESSPRI with different hyposalivation tests

Correlation between Xerostomia index, Clinical Oral Dryness Scale, and ESSPRI with different hyposalivation tests

A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren’s syndrome

Radiological patterns and pulmonary function values of lung involvement in primary Sjögren’s syndrome: A pilot analysis

Contact Info

Product

Resources

About